Evercore ISI lowered the firm’s price target on Becton Dickinson to $285 from $290 and keeps an Outperform rating on the shares and is adding the stock to the firm’s “Tactical Outperform” list ahead of earnings. In an earnings preview for the MedTech, Life Science Tools and Diagnostics group, the firm calls Becton Dickinson “one of the few stocks” with a reasonable valuation and revenue growth set to accelerate. Shares should re-rate if managment reaffirms 9% organic growth expectations for Q4, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- 3 Best Healthcare Stocks to Buy in June 2024, as per Analysts
- M&A News: BDX Snaps Up Edwards Life’s Critical Care Unit in $4.2B Deal
- Becton Dickinson’s $4.2B Acquisition of Edwards Lifesciences Group
- Becton Dickinson to acquire critical care product group from Edwards for $4.2B
- BD to Acquire Edwards Lifesciences’ Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader